<DOC>
	<DOCNO>NCT02381353</DOCNO>
	<brief_summary>After surgery remove eye , either enucleation evisceration , patient variable level pain several postoperative day . Some patient almost discomfort others require significant amount oral narcotic report pain 10 10 numerical rating scale . The current operative standard infiltrate eye socket 0.5 % bupivacaine surgery lead several hour postoperative analgesia . In 2011 , Pacira Pharmaceuticals release bupivacaine liposomal injectable suspension ( Exparel , 1.3 % ) offer sustained release bupivacaine give postoperative pain control 72 hour . This medication use numerous surgery include inguinal hernia repair , hemorrhoidectomy , bunionectomy , breast reconstruction , orthopedic surgery , literature report improve pain control , decrease use oral opioids , increase patient satisfaction . There report use Exparel ophthalmic literature . The investigator propose randomize , control trial compare postoperative pain control offer sustained release bupivacaine offer standard plain bupivacaine enucleation evisceration .</brief_summary>
	<brief_title>Exparel Injection Postoperative Orbital Pain</brief_title>
	<detailed_description />
	<mesh_term>Pain , Postoperative</mesh_term>
	<mesh_term>Bupivacaine</mesh_term>
	<criteria>Inclusion criterion : 1 . All patient undergo enucleation evisceration eye whose surgery perform Department Ophthalmology Mayo Clinic Rochester 2 . Willing able comprehend numerical rating scale system provide score ass pain , nausea , satisfaction level . Exclusion criterion : 1 . Age le 18 year ( Exparel test pediatric population ) 2 . Pregnant nursing ( Exparel test patient population )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Enucleation</keyword>
	<keyword>Evisceration</keyword>
	<keyword>Exparel</keyword>
	<keyword>bupivacaine</keyword>
</DOC>